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  Purpose: A chemosensitivity test can reflect the dif-
ferences in responses of individual cancer patients to 
chemotherapeutic agents. The adenosine triphosphate- 
based chemotherapy response assay (ATP-CRA)is an 
accurate method, which does not require a large amount 
of tissue specimen. So far, no studies have evaluated 
the utility of the ATP-CRA in Korea. Therefore, we in-
vestigated the clinical usefulness of the ATP-CRA in 53 
patients with lung cancer.
  Materials and Methods: Tumor tissues were obtained 
from bronchoscopic biopsies or surgical resections. The 
validity of ATP-CRA was assessed focusing on the  
success rate, experimental error level (intraassay mean 
coefficient of variation [CV]) and reproducibility.
  Results: The overall success rate of ATP-CRA was 
90.6%  (48/53). Normal cells were effectively eliminated
from the tumor tissues with the use of ficoll gradient 
centrifugation and immunomagnetic separation, which 
was confirmed using loss of heterozygosity analysis of 
the 3p deletion. The mean CV of ATP assays was 10.5±
4.6% . The reproducibility of ATP assays was 94±3.8%.
The results of the ATP assays were reported to physicians 
within 7 days of specimen collection. More than 6 anti-
cancer drugs were tested on the tumor specimens ob-
tained from bronchoscopic biopsies. 
  Conclusion: The ATP-CRA is a stable, accurate and 
potentially practical chemosensitivity test in patients with 
lung cancer. (Cancer Res Treat. 2005;37:223-227)
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INTRODUCTION
  Lung cancer is the leading cause of cancer death in Korea 
(1). Anticancer chemotherapy is the main treatment modality 
for small cell lung cancer (SCLC) and advanced non-small cell 
lung cancer (NSCLC). In some recent studies, a survival benefit 
has been demonstrated with adjuvant chemotherapy in patients 
with completely resected NSCLC (2,3). Thus, the importance 
of anticancer chemotherapy for lung cancer is being reapp-
raised. 
  The chemosensitivity test (CST) is an in vitro predictive assay 
for assessing the sensitivity of cancer cells to various 
chemotherapeutic agents, but poses some problems that limit 
its application in clinical practice; for example, it is time- 
consuming (14 to 21 days), has a low success rate (less than 
60%) and requires a large amount of tissue specimens (4). The 
ATP-based chemosensitivity test (ATP assay) has some advan-
tages over other CSTs; it is more sensitive in predicting cell 
viability, eliminates or suppresses normal cells from tumor 
tissues and does not require a large amount of specimens (5～
8). Intracellular ATP is the basic energy source for all living 
cells, and disappears rapidly when cells lose their viabilities. 
Loss of cell viability after treatment with chemotherapeutic 
agents results in decreased cellular ATP levels. Thus, an ATP 
assay can analyze the cytotoxic effects of anticancer drugs by 
measuring the amount of ATP. Its clinical applications to 
melanomas, and ovarian, breast and stomach cancers have been 
reported (9～17). Recently, correlations between drug sensi-
tivity in the ATP assay and the survival benefit in patients with 
ovarian cancer were observed (16,17). 
  So far, no studies have evaluated the utility of the ATP assay 
in Korea. Therefore, we conducted this study to investigate cli-
nical usefulness of the ATP assay in patients with lung cancer, 
focusing on the success rate, experimental error level and 
reproducibility.
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MATERIALS AND METHODS
    1) Subjects
  Fifty-three patients, who underwent a bronchoscopic biopsy 
(n=45), or surgical resection (n=8) for the diagnosis and treat-
ment of lung cancer at The Severance Hospital, Yonsei 
University College of Medicine, between December 2003 and 
February 2005, were included in this study. An informed 
consent for participation was obtained from all patients.
    2) Isolation of cancer cells, elimination of normal cells, 
and tissue culture
  Tumor tissues stored in HBSS (GIBCO BRL Rockville, 
MD), containing 100 IU/ml penicillin (Sigma, St Louis, MO), 
100μg/ml streptomycin (Sigma), 100μg/ml gentamicin (GIB-
CO BRL), 2.5μg/ml amphotericin B (GIBCO BRL) and 5% 
fetal bovine serum (FBS, GIBCO BRL), were delivered to the 
laboratory. These tissues underwent washing, quantification and 
mincing, followed by incubation with extracellular matrix- 
degrading enzymes, such as dispase (Sigma), pronase (Sigma) 
and DNase (Sigma), at 37oC for 12 to 16 hours. Cells were 
harvested using a cell strainer (BD Falcon, Bedford, MA). To 
eliminate normal cells, the cell suspensions were subjected to 
ficoll (1.077 g/ml) gradient centrifugation, at 400 g for 15 min, 
and anti-CD45 antibody conjugated magnetic beads (Miltenyi 
Biotech, Auburn, CA). The viability of isolated cells was tested 
using trypan blue exclusion. A QIAamp DNA mini Kit 
(QIAGEN, Hilden, Germany) was used for DNA extraction 
from cancer and normal tissues, and from cells collected after 
enzymatic disaggregation, ficoll gradient centrifugation and 
immunomagnetic separation. In the cases of surgically resected 
tissues, normal tissues adjacent to tumors were also obtained 
for the purpose of a 3p deletion analysis. PCR was performed 
using three loss of heterozygosity (LOH) markers (D3S1611, 
D3S1612 and D3S1300) specific to the short arm of chromo-
some 3; with LOH analysis performed using a Genetic Analy-
zer (Applied Biosystems, Foster City, CA). The histological 
types of the tumor tissues, as well as qualitative and quan-
titative analyses of cancer cells were evaluated by two patho-
logists (H Kim and D-H Shin).
    3) Anticancer drug treatment and ATP assay
  Separated tumor cells were diluted to 2,000～20,000 viable 
cells/100μl using IMDM (GIBCO BRL), including 10% FBS, 
and seeded in triplicate to a 96-well ultra low attachment 
microplate (Costar, Cambridge, MA), which was able to restrict 
growing normal cells, such as fibroblasts. In the treated groups, 
100μl of chemotherapeutic agents were added on the seeded 
cells and cultured for 48hrs in a CO2 incubator. In the untreated 
control groups, 100μl of IMDM, without chemotherapeutic 
agents, was added to 3～6 wells of the microplate. For the 
purpose of quality control, a negative control group of 3～6 
wells (only seeding medium without cells) and two positive 
control groups were included in the culture plate. Each positive 
control group was composed of 3 wells that contained the 
minimal (105 pg ATP) and median (280 pg ATP) amounts of 
ATP, as measured in 1,000 tumor cells harvested from tissue. 
The final concentrations of anticancer drugs were determined 
by training set experiments, which exhibited scattered distri-
bution of cell deaths from each specimen (data not shown); 
cisplatin (2.5μg/ml), carboplatin (12μg/ml), paclitaxel (8.5μ
g/ml), docetaxel (3.7μg/ml), gemcitabine (16.9μg/ml), vino-
relbine (0.18μg/ml) and irinotecan (4.7μg/ml). Cells from the 
untreated control and treated groups were lysed, and the 
amounts of ATP in the cell lysates measured using luciferin 
and excessive luciferase (Roche, Mannheim, Germany), fol-
lowed by flash type luminescence measurements on a Victor 
3 multi-label counter (PerkinElmer Boston, MA). The cell death 
rate for each drug was calculated as follows: 
mean luminescence in treated group
Cell death = (1-󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏)×100
 rate (%) mean luminescence in untreated 
controls group
  To calculate the intraassay mean coefficient of variation 
(CV) value, luminescence values of each specimen were 
measured 3 times. We then confirmed whether the measured 
values at 280 pg of ATP were higher than those at 105. If there 
were microorganism contamination, inadequate number of cells 
and an intraassay mean CV greater than 30, the test was 
considered a failure. If the measured values in the untreated 
control were lower than those in the positive group (105 pg 
of ATP), the specimen was considered to have unacceptable 
viability. The subject of assay reproducibility testing was 
confined to the tissues obtained from surgical resections, and 
the ATP-CRA performed by different examiners. A compa-
rative method was used to compare the area displayed in the 
cell death graph (18). 
RESULTS
    1) Success rate of tissue culture and isolation of cancer 
cells 
  Of the 53 patients, 5 were excluded from this study due to 
the following reasons: three tumor specimens had unacceptable 
viabilities for obtaining reliable results, as the measured values 
of the untreated control were lower than those of the positive 
control group (105 pg ATP), microorganism contamination was 
observed in one specimen, and one specimen did not yield an 
adequate number of cells. All 5 of these tumor specimens were 
obtained from bronchoscopic biopsies. The success rates of 
ATP-CRA using specimens from surgical resections or bron-
choscopic biopsies were 100 (8/8) and 88.9% (40/45), respec-
tively, with an overall success rate of ATP-CRA was 90.6% 
(48/53). The number of specimens per patient obtained from 
bronchoscopic biopsies varied from 2 to 6 pieces. The mean 
weight of the tissues obtained from the bronchoscopic biopsies 
and surgical resections were 25.4±15.1 mg (mean±standard 
deviation [SD]) and 329.4±202.6 mg, respectively. The mean 
viability of cells separated by enzymatic disaggregation was 
93.3±7.1%. The mean number of cells acquired per 1mg of 
cancer tissue was 28,323±31,111. Lung cancer cells were 
present in all 48 specimens. The histological types of lung ca
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Table 1. Characteristics of the patients
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Characteristics No. of patients (N=48)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Age, years
Median 59
Range 33～76
Sex
Male 34
Female 14
Histological type
NSCLC*
  Adenocarcinoma 23
  Squamous cell carcinoma 17
  Adenosquamous carcinoma  2
  Pleomorphic carcinoma  1
SCLC†  5
Stage
NSCLC
  Stage II  1
  Stage III 13
  Stage IV 29
SCLC
  Limited  2
  Extensive  3
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
*non-small cell lung cancer, †small cell lung cancer.
Table 2. LOH analysis of the 3p deletion in two lung cancer 
patients, both before and after cancer cell fractionation
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Patient 1 Patient 2Marker Samples Intensity of deleted allele*
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
D3S1300 Cancer tissue 1.03†
  D‡ 0.54 Homozygote  F§ 0.50
  I∥ 0.19
D3S1611 Cancer tissue 0.95 0.63
  D 1.0 0.71
  F 0.95 0.85
  I 0.95 0.47
D3S1612 Cancer tissue 0.96
  D 1.16 Homozygote  F 1.18
  I 0.78
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
*The intensity denotes the amplified product of the deleted allele 
from cancer cells and the non deleted allele from contaminated 
normal cells. Therefore, the lower values indicate a decrease in the 
proportion of contaminated normal cells.
signal intensity of deleted allele†unit = 󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
signal intensity of normal allele
‡after disaggregation, §after ficoll gradient centrifugation, ∥after 
immunomagnetic separation.
Fig. 1. 3p deletion analysis according to the cancer cell fractiona-
tion. 3p deletion analysis was performed using D3S1611 
in patient 2. The degree of 3p deletion increased according 
to the immunomagnetic separation. This result indicates 
that adequate cancer cell fractionation was achieved.
ncer were as follows; small cell lung cancer (n=5), adenocar-
cinoma (n=23), squamous cell carcinoma (n=17), adenosquam-
ous carcinoma (n=2) and pleomorphic carcinoma (n=1) (Table 1).
    2) Evaluation of normal cell elimination
  Table 2 and Fig. 1 show representative results of the two 
patients. A normal cell eliminating effect was observed at 
D3S1300 in patient 1, which became clear after the ficoll 
gradient centrifugation. In patient 2, normal cell eliminating 
effects were observed at D3S1611 and D3S1612, but these 
became obvious only after additional immunomagnetic separa-
tion. PCR-LOH analysis was not feasible for tissues with 
homozygosity. One patient (patient 1) exhibited no allelic loss 
at the D3S1611 marker.
    3) Chemosensitivity of lung cancer cells measured by 
ATP assay
  The results of the ATP-CRA were reported within 7 days 
of obtaining the tumor tissue in all cases. The number of 
chemotherapeutic agents tested per tumor specimen for all cases 
and from the bronchoscopic biopsies were 6.3±1.4 (mean±
SD; range, three to 12) and 6.2±1.3, respectively. Using the 
tissues obtained from surgical resections, all chemotherapeutic 
agents available were tested for the ATP-CRA. The list of 
chemotherapeutic agents tested, and their corresponding results, 
are presented in Table 3. The cytotoxic effects for the same 
concentration of the chemotherapeutic agents on cell death 
ranged from 0 to 77% (Table 3, Fig. 2). Cisplatin showed the 
highest median cell death rate value (39.8%) and the widest 
range of cytotoxic effects (6.5～76.7%). Irinotecan showed the 
lowest median cell death rate value (4.5%) and gemcitabine 
showed the narrowest range of cytotoxic effects (0～48%). The 
measured values of the negative control group were low enough 
to be ignored, and no reverse tendency of measured values 
between the two positive control groups was observed. The 
mean CV of the ATP-CRA was 10.5±4.6% (range, 3.3 to 
21.8). In 2 of the surgically resected specimens, two examiners 
performed reproducibility tests using equally-divided speci-
mens. In 4 other surgically resected specimens, three examiners 
performed reproducibility tests by dividing the specimens into 
3 pieces, and the results compared. A total of 14 reproducibility 
tests were performed. The mean value of reproducibility was 
94±3.8% (range, 86.7 to 99.2%).
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Table 3. Summary of chemosensitivity data 
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Cisplatin Carboplatin Gemcitabine Vinorelbine Paclitaxel Docetaxel Irinotecan
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
No. of patients 48 25 45 44 48 46 29 
Mean* (%) 40.7 24.4 23.2 30.6 14.6 16.8 11.8
Median* (%) 39.8 25.3 22.8 31.3  7.25 14.8  4.5
Range* (%) 6.5～76.6 0～57 0～48 0～65.3 0～56.2 0～65.6 0～66.5
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
*Unit: cell death rate.
Fig. 2. Cytotoxic effect of 7 anticancer drugs. A scatter gram shows 
the heterogeneity of the chemosensitivity for anticancer 
drugs in the indicated number of lung cancer patients. A 
broad range of chemosensitivity to the same concentration 
of anticancer drug was noted.
DISCUSSION
  Chemosensitivity tests can reflect differences in the response 
of individual cancer patients to chemotherapeutic agents. The 
in vitro chemosensitivity assays showed an overall sensitivity 
and specificity of 85 and 80%, respectively (19). Recently, a 
meta-analysis demonstrated that the response rate to assay- 
guided chemotherapy was slightly higher than that with 
standard chemotherapy (27 vs. 18%) when CST was applied 
in clinical practice (20). 
  The ATP assay can be performed with a very small amount 
of cancer tissue, and effectively eliminates or suppresses normal 
cells from the tissue specimens and is more accurate than 
previous CSTs, such as the MTT assay (5～8). Therefore, the 
ATP assay is widely used in Western countries. In this study, 
the ATP assay was applied to patients with lung cancer to 
investigate its clinical utility as a CST. 
  The results of the ATP-CRA were reported to physicians 
within 7 days of specimen collection; thus, chemotherapy could 
be initiated without any delay. The success rate of the ATP- 
CRA was 90.6%, which was similar or even superior to those 
in other countries (10,13～15,17,21). The mean CV of the test 
was 10.5%, which was also superior to a previous study 
(13.0%) (21). High reproducibility rates were observed for all 
cases when the tests were repeated by different examiners. The 
ATP-CRA could be applied to specimens obtained from bro-
nchoscopic biopsies using more than 6 anticancer drugs. From 
the above results, the ATP-CRA was confirmed to be a stable, 
accurate and potentially practical CST method in patients with 
lung cancer.
  All CST involve a process that directly measures the number 
of viable cells after treatment with cytotoxic drugs. Early 
methods measured the ability of living cells to form colonies 
or to uptake isotope-labeled thymidine, while recent methods 
measure the number of living cells from the amount of ATP, 
dehydrogenase enzyme activity (MTT, HDRA) and integrity of 
cell membrane (DiSC) in order to shorten the turnaround time 
and improve the success rates (22). Contrary to the DiSC assay, 
which is dependent on the morphologic differences between 
cancer and normal cells, the measurement of the amount of 
ATP or the enzyme activity may be affected by contaminated 
normal cells within the cancer tissue (23,24). Therefore, it is 
important to eliminate and inhibit the proliferation of normal 
cells. In this study, we demonstrated that normal cells were 
effectively eliminated from the tumor tissue using ficoll 
gradient centrifugation and CD45 immunomagnetic separation. 
  A wide range of cell deaths was observed in this study. 
Cisplatin, which forms the backbone of lung cancer che-
motherapy, showed the greatest cytotoxic effect in vitro. Our 
previous study on the validation of APT-CRA for NSCLC pati-
ents predicted the response rates with a sensitivity and spe-
cificity of 83.3 and 100%, respectively (25). Although the 
feasibility of the CST has been established for more than 25 
years, a clear clinical benefit of assay-guided chemotherapy 
remains to be adequately demonstrated in lung cancer. To 
define the clinical benefit of assay-guided chemotherapy based 
on the above results, a clinical trial targeting patients with 
stages IIIB or IV has been initiated at our institute. We are 
currently comparing the response rates and ultimately survival 
outcomes of in vitro best regimens, which are composed of 
cisplatin and other chemotherapeutic agent showing the most 
cytotoxic effects in the ATP-CRA, to empiric chemotherapy.
CONCLUSIONS
  The ATP-CRA is a stable, accurate and potentially practical 
chemosensitivity test method in patients with lung cancer. 
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